Donor Selection
Cross-source consensus on Donor Selection from 1 sources and 5 claims.
1 sources · 5 claims
Benefits
Preparation
Risks & contraindications
Highlighted claims
- Eligible donors are ranked by microbiota profile, and only the top half are used. — Transfer of faeces in ulcerative colitis 2: improving efficacy – study protocol for a multicentre randomised controlled trial (TURN2 study)
- Donors can donate for a maximum of 12 weeks and donated FMT syringes remain quarantined until successful rescreening. — Transfer of faeces in ulcerative colitis 2: improving efficacy – study protocol for a multicentre randomised controlled trial (TURN2 study)
- TURN2 donors are screened using Netherlands Donor Feces Bank protocol, European consensus guidance, and updated infectious-risk guidance. — Transfer of faeces in ulcerative colitis 2: improving efficacy – study protocol for a multicentre randomised controlled trial (TURN2 study)
- TURN2 donor selection favors high alpha diversity and high predicted butyrate production. — Transfer of faeces in ulcerative colitis 2: improving efficacy – study protocol for a multicentre randomised controlled trial (TURN2 study)
- TURN2 donor selection disfavors high Ruminococcus gnavus and Proteobacteria abundance. — Transfer of faeces in ulcerative colitis 2: improving efficacy – study protocol for a multicentre randomised controlled trial (TURN2 study)